Pharmeuropa: Two Revised Chapters on Dissolution Testing published for comments
Recommendation

Tuesday, 10 February 2026 13.00 - 17.30 h
In the Pharmeuropa issue 36.3, two draft chapters related to dissolution testing were published.
The revised chapters align the dissolution testing for lipophilic dosage forms with the general chapter 2.9.3. Dissolution test for solid dosage forms. The structure of the texts have been updated to align both with current Ph. Eur. style and with the structure of 2.9.3 and some editorial changes have been made throughout the text.
2.9.42. Dissolution test for lipophilic solid dosage forms
According to the briefing notes, key updates include:
- "Apparatus: a description and schematic presentation of the two possible configurations have been added; an option to use suitable heating devices other than a water-bath has been added.
- Sampling: the filtration step has been deleted since it is deemed unnecessary for lipophilic dosage forms."
2.9.43. Apparent dissolution
The briefing notes mention the following key changes:
- "Apparatus: description and schematic presentation of the two possible configurations added; option to use suitable heating devices other than a water-bath added. New figure to display the insert added.
- Procedure: aperture size and the wire diameter of the wire cloth screens used corrected."
The deadline for submitting comments is 30 September 2024. The full text and further details on the revision and can be found, after registration, on the Pharmeuropa website.
Related GMP News
03.02.2026Your Input is Requested: AQCG Survey on OOS Investigations
03.02.2026Questions and Answers on System Suitability Tests (SST) - Part 2
03.02.2026Eurachem Publishes New Guide on the Fitness for Intended Use of Analytical Equipment and Systems
14.01.2026FDA Warning Letter: OOS Handling and HPLC Method Validation
07.01.2026Revised Ph. Eur. Chapters 2.9.42 and 2.9.43 on Dissolution Testing
07.01.2026Korean MFDS Publishes Data Collection on Dissolution Test Methods


